|
|
RepliCel Announces Material Patent Milestones
|
Vancouver, BC, January 17, 2022--RepliCel Life Sciences Inc. (OTCPK: REPCF, TSXV: RP), a company developing novel, next-generation injection technologies as well as regenerative medicine products in aesthetics and orthopedics, announced the filing of a new patent application covering novel aspects of the DermaPrecise product portfolio as well as the granting and/or allowance of three patent applications in key markets.
|
|
|
|
|
|
RepliCel Announces Dermal Injector Update
|
Vancouver, BC, November 9, 2021--RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2), a company developing next-generation technologies in aesthetics and orthopedics, provided an update on its dermal injector program.
|
|
|
|
|
|
RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies
|
Vancouver, BC, July 14, 2021--RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2), a company developing next-generation technologies in aesthetics and orthopedics, announced that it has submitted its application to Japan's Ministry of Health, Labour, and Welfare (MHLW) for approval to manufacture the Company's RCT-01 cell therapy for chronic tendinopathy and RCS-01 cell therapy for aging and sun-damaged skin for its upcoming clinical studies.
|
|
|
|
|
|
Vancouver-based RepliCel Launches Testing of Dermal Injector Units
|
Vancouver, BC, June 2, 2021--RepliCel Life Sciences Inc. (TSX.V:RP) (OTCPK:REPCF), a company developing next-generation technologies in aesthetics and orthopedics, announced that it has received the first units of its dermal injector and is nearing completion of the preliminary phase of functional testing required to launch executing on the larger-scale production and testing plan.
|
|
|
|
|
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies
|
Vancouver, BC, May 28, 2021--RepliCel Life Sciences Inc. (TSXV: RP), a company developing next-generation technologies in aesthetics and orthopedics, announced that it has retained leading clinical research organization, Accerise Inc, with offices in Tokyo and Osaka, to lead the planning and preparations for clinical research studies of RepliCel's skin rejuvenation (RCS-01) and tendon regeneration (RCT-01) cell therapy products in Japan.
|
|
|
|
|
|